Targeted therapy for cancer using PARP inhibitors

Current Opinion in Pharmacology

Volumn 8, Issue 4, 2008, Pages 363-369

  Lord, Christopher J ^a   Ashworth, Alan ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOBENZAMIDE; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; ABT 888; AG 0146999; ANTINEOPLASTIC AGENT; AZD 2281; BRCA1 PROTEIN; BRCA2 PROTEIN; BSI 201; CARBOPLATIN; CISPLATIN; DACARBAZINE; DIMETHYL SULFATE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEMCITABINE; HISTONE H1; IRINOTECAN; KU 0058684; KU 0058948; KU 0059436; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROGESTERONE RECEPTOR; RAD51 PROTEIN; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XRCC1 PROTEIN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; DNA REPAIR; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG TARGETING; GENE MUTATION; GENETIC RISK; HUMAN; LOW DRUG DOSE; MELANOMA; MONOTHERAPY; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENES, BRCA1; GENES, BRCA2; HUMANS; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; SUBSTRATE SPECIFICITY;

EID: 51449113045     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.06.016     Document Type: Review

References (41)

1. Wooster R., and Weber B.L. Breast and ovarian cancer. N Engl J Med 348 (2003) 2339-2347
2. Gudmundsdottir K., and Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25 (2006) 5864-5874
3. Tutt A., Bertwistle D., Valentine J., Gabriel A., Swift S., Ross G., Griffin C., Thacker J., and Ashworth A. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 20 (2001) 4704-4716
4. Moynahan M.E., Pierce A.J., and Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 7 (2001) 263-272
5. Moynahan M.E., Chiu J.W., Koller B.H., and Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell 4 (1999) 511-518
6. Narod S.A., and Foulkes W.D. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4 (2004) 665-676
7. Tutt A.N., Lord C.J., McCabe N., Farmer H., Turner N., Martin N.M., Jackson S.P., Smith G.C., and Ashworth A. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 70 (2005) 139-148
8. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., and Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 434 (2005) 913-917
9. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921. These two reports describe the synthetic lethality between PARP and BRCA1 or BRCA2 and demonstrate the profound sensitivity of BRCA-deficient cells for drug like PARP inhibitors.
10. Boulton S., Kyle S., and Durkacz B.W. Interactive effects of inhibitors of poly (ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis 20 (1999) 199-203
11. Saffhill R., and Ockey C.H. Strand breaks arising from the repair of the 5-bromodeoxyuridine-substituted template and methyl methanesulphonate-induced lesions can explain the formation of sister chromatid exchanges. Chromosoma 92 (1985) 218-224
12. Schultz N., Lopez E., Saleh-Gohari N., and Helleday T. Poly (ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res 31 (2003) 4959-4964
13. McCabe N., Turner N.C., Lord C.J., Kluzek K., Bialkowska A., Swift S., Giavara S., O'Connor M.J., Tutt A.N., Zdzienicka M.Z., et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-Ribose) polymerase inhibition. Cancer Res 66 (2006) 8109-8115
14. Hartwell L.H., Szankasi P., Roberts C.J., Murray A.W., and Friend S.H. Integrating genetic approaches into the discovery of anticancer drugs. Science 278 (1997) 1064-1068
15. Kaelin Jr. W.G. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5 (2005) 689-698. These two reviews summarise how genetic differences between tumour and normal cells may be exploited in designing therapeutic approaches for cancer. Particular emphasis is given to the idea of exploiting synthetic lethality.
16. Gagne J.P., Hendzel M.J., Droit A., and Poirier G.G. The expanding role of poly (ADP-ribose) metabolism: current challenges and new perspectives. Curr Opin Cell Biol 18 (2006) 145-151
17. Ame J.C., Spenlehauer C., and de Murcia G. The PARP superfamily. Bioessays 26 (2004) 882-893
18. Otto H., Reche P.A., Bazan F., Dittmar K., Haag F., and Koch-Nolte F. In silico characterization of the family of PARP-like poly (ADP-ribosyl) transferases (pARTs). BMC Genomics 6 (2005) 139. These two papers detail the growing body of work describing the PARP superfamily.
19. Dantzer F., Ame J.C., Schreiber V., Nakamura J., Menissier-de Murcia J., and de Murcia G. Poly (ADP-ribose) polymerase-1 activation during DNA damage and repair. Methods Enzymol 409 (2006) 493-510
20. Zaremba T., and Curtin N.J. PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med Chem 7 (2007) 515-523. This review provides a detailed account of the medicinal chemistry underlying the development of PARP inhibitors.
21. Plummer E.R., and Calvert H. Targeting poly (ADP-ribose) polymerase: a two-armed strategy for cancer therapy. Clin Cancer Res 13 (2007) 6252-6256
22. Yap T.A., Boss D.S., Fong P.C., Roelvink M., Tutt A., Carmichael J., O'Connor M.J., Kaye S.B., Schellens J.H., and de Bono J.S. First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers. J Clin Oncol 25 (2007) 2007-3529. This paper describes the preliminary results of a phase I trial of a PARP inhibitor as monotherapy for cancer. A number of patients with BRCA mutations show sustained responses to the drug.
23. Turner N., Tutt A., and Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4 (2004) 814-819
24. Reis-Filho J.S., and Tutt A.N. Triple negative tumours: a critical review. Histopathology 52 (2008) 108-118
25. McCabe N., Lord C.J., Tutt A.N., Martin N.M., Smith G.C., and Ashworth A. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther 4 (2005) 934-936. Early reports questioned the efficacy of PARP inhibitors in human tumour cells bearing pathogenic BRCA mutations. This paper describes the sensitivity of a human tumour cell line bearing such a mutation to a drug-like PARP inhibitor.
26. Donawho C.K., Luo Y., Luo Y., Penning T.D., Bauch J.L., Bouska J.J., Bontcheva-Diaz V.D., Cox B.F., DeWeese T.L., Dillehay L.E., et al. ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13 (2007) 2728-2737
27. Perkins E., Sun D., Nguyen A., Tulac S., Francesco M., Tavana H., Nguyen H., Tugendreich S., Barthmaier P., Couto J., et al. Novel inhibitors of poly (ADP-ribose) polymerase/PARP1 and PARP2 identified using a cell-based screen in yeast. Cancer Res 61 (2001) 4175-4183
28. Yelamos J., Schreiber V., and Dantzer F. Toward specific functions of poly (ADP-ribose) polymerase-2. Trends Mol Med 14 (2008) 169-178
29. Loh Jr. V.M., Cockcroft X.L., Dillon K.J., Dixon L., Drzewiecki J., Eversley P.J., Gomez S., Hoare J., Kerrigan F., Matthews I.T., et al. Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly (ADP-ribose) polymerase. Bioorg Med Chem Lett 15 (2005) 2235-2238
30. Calabrese C.R., Almassy R., Barton S., Batey M.A., Calvert A.H., Canan-Koch S., Durkacz B.W., Hostomsky Z., Kumpf R.A., Kyle S., et al. Anticancer chemosensitization and radiosensitization by the novel poly (ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96 (2004) 56-67
31. Oliver A.W., Ame J.C., Roe S.M., Good V., de Murcia G., and Pearl L.H. Crystal structure of the catalytic fragment of murine poly (ADP-ribose) polymerase-2. Nucleic Acids Res 32 (2004) 456-464
32. Matsumoto K., Kondo K., Ota T., Kawashima A., Kitamura K., and Ishida T. Binding mode of novel 1-substituted quinazoline derivatives to poly (ADP-ribose) polymerase-catalytic domain, revealed by X-ray crystal structure analysis of complexes. Biochim Biophys Acta 1764 (2006) 913-919
33. Edwards S.L., Brough R., Lord C.J., Natrajan R., Vatcheva R., Levine D.A., Boyd J., Reis-Filho J.S., and Ashworth A. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451 (2008) 1111-1115
34. Sakai W., Swisher E.M., Karlan B.Y., Agarwal M.K., Higgins J., Friedman C., Villegas E., Jacquemont C., Farrugia D.J., Couch F.J., et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451 (2008) 1116-1120. These two papers describe intragenic mutation of BRCA2 as a mechanism for resistance to PARP inhibitors.
35. Swisher E., Sakai W., Karlan B., Wurz K., Urban N., and Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 68 (2008) 2581-2586
36. Iorns E., Lord C.J., Turner N., and Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 6 (2007) 556-568
37. Turner N., Lord C., Iorns E., Brough R., Swift S., Elliott R., Rayter S., Smith A., Tutt A., and Ashworth A. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J 27 (2008) 1368-1377
38. Hay T., Jenkins H., Sansom O.J., Martin N.M., Smith G.C., and Clarke A.R. Efficient deletion of normal Brca2-deficient intestinal epithelium by poly (ADP-ribose) polymerase inhibition models potential prophylactic therapy. Cancer Res 65 (2005) 10145-10148
39. Liu S., Ginestier C., Charafe-Jauffret E., Foco H., Kleer C.G., Merajver S.D., Dontu G., and Wicha M.S. BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A 105 (2008) 1680-1685
40. Tong W.M., Yang Y.G., Cao W.H., Galendo D., Frappart L., Shen Y., and Wang Z.Q. Poly (ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice. Oncogene 26 (2007) 3857-3867
41. Helleday T., Bryant H.E., and Schultz N. Poly (ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 4 (2005) 1176-1178